The Role of Fluorodeoxyglucose, 18F-Dihydroxyphenylalanine, 18F-Choline, and 18F-Fluoride in Bone Imaging with Emphasis on Prostate and Breast

Cook, 2000, The role of positron emission tomography in the management of bone metastases, Cancer Suppl, 88, 2927, 10.1002/1097-0142(20000615)88:12+<2927::AID-CNCR8>3.0.CO;2-V Valk, 1996, Cost-effectiveness of PET imaging in clinical oncology, Nucl Med Biol, 23, 737, 10.1016/0969-8051(96)00080-7 Gambhir, 1998, Analytical decision model for the cost-effective management of solitary pulmonary nodules, J Clin Oncol, 16, 2113, 10.1200/JCO.1998.16.6.2113 Even-Sapir, 2004, Assessment of malignant skeletal disease, J Nucl Med, 45, 272 Fogelman, 2005, Positron emission tomography and bone metastases, Semin Nucl Med, 35, 135, 10.1053/j.semnuclmed.2004.11.005 Minn, 1996, Influence of hypoxia on tracer accumulation in squamous cell carcinoma, Nucl Med Biol, 23, 941, 10.1016/S0969-8051(96)00134-5 Petren-Mallmin, 1998, Skeletal metastases from breast cancer, Skel Radiol, 27, 72, 10.1007/s002560050340 Hoegerle, 2001, 18F–DOPA positron emission tomography for tumor detection in patients with medullary thyroid carcinoma and elevated calcitonin levels, Eur J Nucl Med, 28, 64, 10.1007/s002590000404 Mundy, 2002, Metastasis to bone, Nat Rev Cancer, 2, 584, 10.1038/nrc867 Kahn, 1994, Positron emission tomographic measurement of bone marrow blood flow to the pelvis and lumbar vertebrae in young normal adults, Blood, 83, 958, 10.1182/blood.V83.4.958.958 Jacobson, 1996, Bone scanning in metastatic disease, 87 O’Mara, 1976, Skeletal scanning in neoplastic disease, Cancer, 37, 480, 10.1002/1097-0142(197601)37:1+<480::AID-CNCR2820370713>3.0.CO;2-2 Horiuchi-Suzuki, 2004, What is the source of the skeletal affinity of 99mTC-V-DMSA?, Eur J Nucl Med Mol Imaging, 31, 1675, 10.1007/s00259-004-1651-5 Cook, 2001, The role of nuclear medicine in monitoring treatment in skeletal malignancy, Semin Nucl Med, 31, 206, 10.1053/snuc.2001.23527 Koizumi, 1999, Bone metabolic markers in the evaluation of bone scan flare phenomenon in bone metastases of breast cancer, Clin Nucl Med, 24, 15, 10.1097/00003072-199901000-00004 Schirrmeister H, Guhlmann A, Elsner K, et al: Sensitivity in detecting osseous lesions depends on anatomic localization: Planar bone scintigraphy versus 18F PET. J Nucl Med 40:1623-1629 Bury, 1998, Flourine-18 deoxyglucose positron emission tomography for the detection of bone mestastases in patients with non-small cell lung cancer, Eur J Nucl Med, 25, 1244, 10.1007/s002590050291 Schaner, 1978, Comparison of computed and conventional whole lung tomography in detecting pulmonary nodules, Am J Roentgenol, 131, 51, 10.2214/ajr.131.1.51 Vanel, 1984, Pulmonary evaluation of patients with osteosarcoma, Am J Roentgenol, 143, 519, 10.2214/ajr.143.3.519 Muhm, 1978, Comparison of whole lung tomography and computed tomography for detecting pulmonary nodules, Am J Roentgenol, 131, 981, 10.2214/ajr.131.6.981 Alavi, 2004, Implications of PET based molecular imaging on the current and future practice of medicine, Semin Nucl Med, 34, 56, 10.1053/j.semnuclmed.2003.09.007 Crim, 1989, Magnetic resonance imaging of the hindfoot, Foot Ankle, 10, 1, 10.1177/107110078901000101 Hilpert, 1986, MRI of hemorrhagic renal cysts in polycystic kidney disease, Am J Roentgenol, 146, 1167, 10.2214/ajr.146.6.1167 Semelka, 1994, Solitary hepatic metastasis, J Magn Reson Imaging, 4, 319, 10.1002/jmri.1880040316 Stark, 1987, Hepatic metastases, Radiology, 165, 399, 10.1148/radiology.165.2.3310094 Haubold-Reuter, 1993, The value of bone scintigraphy, bone marrow scintigraphy and fast spin-echo magnetic resonance imaging in staging of patients with malignant solid tumors, Eur J Nucl Med, 20, 1063, 10.1007/BF00173484 Kosuda, 1996, Does bone SPECT actually have lower sensitivity for detecting vertebral metastasis than MRI, J Nucl Med, 37, 975 Athanasoulis, 2004, What is the source of the skeletal affinity of 99mTC-V-DMSA?, Eur J Nucl Med Mol Imaging, 31, 1673, 10.1007/s00259-004-1650-6 Smoker, 1987, The role of MR imaging in evaluating metastatic spinal disease, Am J Roentgenol, 149, 1241, 10.2214/ajr.149.6.1241 Frank, 1990, Detection of malignant bone tumors, Am J Roentgenol, 55, 1043, 10.2214/ajr.155.5.2120933 Steinborn, 1999, Wholebody bone marrow MRI in patients with metastatic disease to the skeletal system, J Comput Assist Tomogr, 23, 123, 10.1097/00004728-199901000-00026 Calautti, 2003, Functional neuroimaging studies of motor recovery after stroke in adults, Stroke, 34, 1553, 10.1161/01.STR.0000071761.36075.A6 Grenier, 2003, Functional MRI of the kidney, Abdom Imaging, 28, 164, 10.1007/s00261-001-0183-8 Hetzel, 2004, Reliability of symptoms to determine use of bone scans to identify bone metastases in lung cancer, Br Med J, 328, 1051, 10.1136/bmj.328.7447.1051 Schirrmeister, 2004, Omission of bone scanning according to staging guidelines leads to futile therapy in non-small cell lung cancer, Eur J Nucl Med Mol Imaging, 31, 964, 10.1007/s00259-004-1492-2 Savelli, 2001, Bone scintigraphy and added value of SPECT (single photon emission tomography) in detecting skeletal lesions, Q J Nucl Med, 45, 27 Roland, 1995, Metastases seen on SPECT imaging despite a normal planar bone scan, Clin Nucl Med, 20, 1052, 10.1097/00003072-199512000-00002 Sedonja, 1999, The benefit of SPECT when added to planar scintigraphy in patients with bone metastases in the spine, Clin Nucl Med, 24, 407, 10.1097/00003072-199906000-00006 Schirrmeister, 2001, Prospective evaluation of the clinical value of planar bone scans, SPECT, and 18F-labeled NaF PET in newly diagnosed lung cancer, J Nucl Med, 42, 1800 Warburg, 1954, On the origin of cancer cells, Science, 123, 306 Aoki, 2001, FDG PET of primary benign and malignant bone tumors, Radiology, 219, 774, 10.1148/radiology.219.3.r01ma08774 Cook, 1998, Detection of bone metastases in breast cancer by 18FDG PET, J Clin Oncol, 16, 3375, 10.1200/JCO.1998.16.10.3375 Galasko, 1986 Paquet, 2004, Within-patient variability of 18F-FDG, J Nucl Med, 45, 784 Keyes, 1995, SUV, J Nucl Med, 36, 1836 Ramos, 2001, 18F-FDG PET standardized uptake values in normal anatomical structures using iterative reconstruction segmented attenuation correction and filtered back-projection, Eur J Nucl Med, 28, 155, 10.1007/s002590000421 Schulte, 1999, Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET, J Nucl Med, 40, 1637 Franzius, 2002, Prognostic significance of (18) F-FDG and (99m) Tc methylene diphosphonate uptake in primary osteosarcoma, J Nucl Med, 43, 1012 Brenner, 2004, Comparison of different quantitative approaches to 18F-fluoride PET scans, J Nucl Med, 45, 1493 Blau, 1962, Fluorine-18, J Nucl Med, 3, 332 Blau, 1972, 18F-Fluoride for bone imaging, Semin Nucl Med, 2, 31, 10.1016/S0001-2998(72)80005-9 Narita, 1990, Distribution of fluoride concentration in the rat’s bone, Calcif Tissue Int, 46, 200, 10.1007/BF02555045 Ishiguro, 1993, Distribution of fluoride in cortical bone of human rib, Calcif Tissue Int, 52, 278, 10.1007/BF00296652 Wootton, 1986, The single-passage extraction of 18F in rabbit bone, Clin Physiol Meas, 7, 333, 10.1088/0143-0815/7/4/003 Schirrmeister, 1998, Darstellung des normalen Skelettsystems mit 18F Na-PET im Vergleich zur konventionellen Skelettszintigraphie mit 99mTc-MDP, Fortschr Röntgenstr, 168, 451, 10.1055/s-2007-1015161 Hawkins, 1992, Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET, J Nucl Med, 33, 633 Wolfenden, 1980, Comparison of bone scintigraphy and radiology in myeloma, Radiology, 134, 723, 10.1148/radiology.134.3.7355226 Fogelman, 1980, Skeletal uptake of diphosphonate, Eur J Nucl Med, 5, 473, 10.1007/BF00252034 Hoh, 1993, Whole body skeletal imaging with (18F) fluoride ion and PET, J Comput Assist Tomogr, 17, 34, 10.1097/00004728-199301000-00005 Cook, 2001, The role of positron emission tomography in skeletal disease, Semin Nucl Med, 31, 50, 10.1053/snuc.2001.18746 Hoegerle, 1998, Combined FDG and (F-18) fluoride whole-body PET, Radiology, 209, 253, 10.1148/radiology.209.1.9769840 Schirrmeister H, Guhlmann A, Kotzerke J, et al: Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol 17:2381-2389 Hetzel, 2003, F-18 NaF PET for detection of bone metastases in lung cancer, J Bone Miner Res, 18, 2206, 10.1359/jbmr.2003.18.12.2206 Kaltsas, 2004, Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumors, Eur J Endocrinol, 151, 15, 10.1530/eje.0.1510015 Eriksson, 2002, The role of PET in localization of neuroendocrine and adrenocortical tumors, Ann NY Acad Sci, 970, 159, 10.1111/j.1749-6632.2002.tb04422.x Bombardieri, 2004, Positron of nuclear medicine techniques in the diagnostic work-up of neuroendocrine tumors, J Nucl Med Mol Imag, 48, 150 Eriksson, 2005, Developments in PET for the detection of endocrine tumors, Best Pract Res Clin Endocrinol Metab, 19, 311, 10.1016/j.beem.2004.11.001 Sundin, 2004, PET in the diagnosis of neuroendocrine tumors, Ann N Y Acad Sci, 1014, 246, 10.1196/annals.1294.027 Li, 2005, The radionuclide molecular imaging and therapy of neuroendocrine tumors, Curr Cancer Drug Targets, 2, 139, 10.2174/1568009053202054 Moul, 2000, Prostate specific antigen only progression of prostate cancer, J Urol, 163, 1632, 10.1016/S0022-5347(05)67511-8 Huch Boni, 1996, Value of endorectal coil versus body coil MRI for diagnosis of recurrent pelvic malignancies, Abdom Imaging, 21, 345, 10.1007/s002619900079 Leventis, 2001, Local recurrence after radical prostatectomy, Radiology, 219, 432, 10.1148/radiology.219.2.r01ma20432 Roudier, 2003, Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer, Clin Exp Metastasis, 20, 171, 10.1023/A:1022627421000 Roehl, 2004, Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients, J Urol, 172, 910, 10.1097/01.ju.0000134888.22332.bb Kamat, 2004, Rise in serum PSA of 1.5 ng/mL above 24-month nadir after external beam radiotherapy is predictive of biochemical failure, Urology, 63, 1132, 10.1016/j.urology.2004.01.010 Partin, 1994, Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases, Urology, 43, 649, 10.1016/0090-4295(94)90180-5 Okotie, 2004, Predictors of metastatic disease in men with biochemical failure following radical prostatectomy, J Urol, 171, 2260, 10.1097/01.ju.0000127734.01845.99 Hermann, 2004, FDG PET for the detection of recurrent/metastatic prostate carcinoma in patients with rising PSA after radical prostatectomy, J Nucl Med, 45, 359 Fricke, 2003, Positron emission tomography with (11) C-acetate and (18) F-FDG in prostate cancer patients, Eur J Nucl Med Mol Imaging, 30, 607, 10.1007/s00259-002-1104-y Larson, 2004, Tumor localization of 16 beta-(18)F- fluoro-5α-dihydrotestosterone versus (18)F-FDG in patients with progressive, metastatic prostate cancer, J Nucl Med, 45, 366 Morris, 2002, Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer, Urology, 59, 913, 10.1016/S0090-4295(02)01509-1 Nunez, 2002, Combined 18 F-FDG and 11 C-methionine PET scans in patients with newly progressive metastatic prostate cancer, J Nucl Med, 43, 46 Hara, 1997, PET imaging of brain tumor with (methyl-11C) choline, J Nucl Med, 38, 842 Hara, 1997, Automated synthesis of fluoroine-18 labeled choline analogue, J Nucl Med, 38, 44 DeGrado, 2001, Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography, Cancer Res, 61, 110 DeGrado, 2001, Synthesis and evaluation of 18F-labeled choline analogs as oncologic PET tracers, J Nucl Med, 42, 1805 Macara, 1989, Elevated phosphocholine concentration in ras-transformed NIH 3T3 cells arises from increased choline kinase activity, not from phosphatidylcholine breakdown, Mol Cell Biol, 9, 325, 10.1128/MCB.9.1.325 Heinisch, 2004, Initial experience in F18-fluorocholine PET/CT in prostate cancer, Q J Nucl Med Mol Imaging, 48, 7 Langsteger, 2005, Diagnosis of prostate cancer with FCH positron emission tomography/computed tomography, Mol Imaging Biol, 7, 113 Jemal, 2004, Cancer statistics, 2004, CA Cancer J Clin, 54, 8, 10.3322/canjclin.54.1.8 Partin, 1997, Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer, JAMA, 277, 1445, 10.1001/jama.1997.03540420041027 Kattan, 1999, Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer, J Clin Oncol, 17, 1499, 10.1200/JCO.1999.17.5.1499 Kattan, 1998, A preoperative nomogram for disease reccurrence following radical prostatectomy for prostate cancer, J Natl Cancer Inst, 90, 766, 10.1093/jnci/90.10.766 D’Amico, 1995, The impact of the inclusion of endorectal coil magnetic resonance imaging in a multivariate analysis to predict clinically unsuspected extraprostatic cancer, Cancer, 75, 2368, 10.1002/1097-0142(19950501)75:9<2368::AID-CNCR2820750929>3.0.CO;2-# Charhon, 1983, Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma special reference to osteomalacia, Cancer, 15, 918, 10.1002/1097-0142(19830301)51:5<918::AID-CNCR2820510526>3.0.CO;2-J Chybowski, 1991, Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer, J Urol, 145, 313, 10.1016/S0022-5347(17)38325-8 Lee, 1997, Using prostate-specific antigen to eliminate the staging radionuclide bone scan, Urol Clin North Am, 24, 389, 10.1016/S0094-0143(05)70385-2 Cher, 1998, Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radial prostatectomy, J Urol, 160, 1387, 10.1016/S0022-5347(01)62545-X Kane, 2003, Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy, Urology, 61, 607, 10.1016/S0090-4295(02)02411-1 Ornstein, 1998, Evaluation and management of men whose radical prostatectomies failed, Urology, 52, 1047, 10.1016/S0090-4295(98)00403-8 Langsteger, 2005, 18F Choline PET/CT in preoperative staging of prostate cancer, Nuklearmedizin, 44, 36 de Jong, 2003, 11C-Choline positron emission tomography for the evaluation after treatment of localized prostate cancer, Eur Urol, 44, 32, 10.1016/S0302-2838(03)00207-0 Heinisch M, Dirisamer A, Loidl W, et al: PET/CT with F-18-fluorocholine for restaging of prostate cancer patients: Meaningful at PSA < 5 ng/ml? Mol Imaging Biol (in press) Coleman, 2000, Preliminary evaluation of F-18 fluorocholine (FCH) as a PET tumor imaging agent, Clin Positron Imaging, 3, 147, 10.1016/S1095-0397(00)00059-5 Shreve, 1996, Metastatic prostate cancer, Radiology, 199, 751, 10.1148/radiology.199.3.8638000 Coleman, 2001, The role of zoledronic acid in cancer, Semin Oncol, 28, 11, 10.1016/S0093-7754(01)90260-X Guise, 1996, Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis, J Clin Invest, 98, 1544, 10.1172/JCI118947 Shen, 2003, PTH-related protein modulated PC-3 prostate cancer cell adhesion and integrin subunit profile, Mol Cell Endocrinol, 199, 165, 10.1016/S0303-7207(02)00287-3 Moon, 1998, Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent of metastatic breast carcinoma, J Nucl Med, 39, 431 Wahl, 1991, Primary and metastatic breast carcinoma, Radiology, 179, 765, 10.1148/radiology.179.3.2027989 Lonneux, 2000, The place of whole-body PET FDG for the diagnosis of distant recurrence of breast cancer, Clin Positron Imaging, 3, 45, 10.1016/S1095-0397(00)00042-X Ohta, 2001, Whole body PET for the evaluation of bony metastases in patients with breast cancer, Nucl Med Commun, 22, 875, 10.1097/00006231-200108000-00005 Yang, 2002, Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer, J Cancer Res Clin Oncol, 128, 325, 10.1007/s00432-002-0342-5 Stafford, 2002, Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy, Acad Radiol, 9, 913, 10.1016/S1076-6332(03)80461-0 Tritz, 1989, Bone marrow involvement in small cell lung cancer, Cancer, 63, 763, 10.1002/1097-0142(19890215)63:4<763::AID-CNCR2820630426>3.0.CO;2-F Bezwoda, 1986, Bone marrow involvement in anaplastic small cell lung cancer, Cancer, 58, 1762, 10.1002/1097-0142(19861015)58:8<1762::AID-CNCR2820580830>3.0.CO;2-V Trillet, 1989, Bone marrow metastases in small cell lung cancer, Br J Cancer, 60, 83, 10.1038/bjc.1989.225 Marom, 1999, Staging non-small cell lung cancer with whole-body PET, Radiology, 212, 803, 10.1148/radiology.212.3.r99se21803 Jadvar, 2004, Musculoskeletal system, Semin Nucl Med, 34, 254, 10.1053/j.semnuclmed.2004.06.002 Tse, 1994, Positron emission tomography diagnosis of pulmonary metastases in osteogenic sarcoma, Am J Clin Oncol, 17, 22, 10.1097/00000421-199402000-00006 Franzius, 2001, FDG-PET for detection of pulmonary metastases from malignant primary bone tumors, Ann Oncol, 12, 479, 10.1023/A:1011111322376 Gayed, 2003, Comparison of bone and 2-deoxy-2-(18F) fluoro-d-glucose positron emission tomography in the evaluation of bony metastases in lung cancer, Mol Imaging Biol, 5, 26, 10.1016/S1536-1632(03)00036-2 Al-Sugair, 1999, Relative diagnostic efficiency of F-18 FDG PET and bone scintigraphy for detection of osseous metastases in primary or secondary lung cancer, J Nucl Med, 40, 20 Garcia, 2003, 99m Tc-MDP bone scintigraphy and 18F FDG positron emission tomography in lung and prostate cancer patients, Eur J Nucl Med Mol Imaging, 30, 1714, 10.1007/s00259-003-1370-3 Lin, 1999, Factors related to the survival of papillary and follicular thyroid carcinoma patients with distant metastases, Thyroid, 9, 1227, 10.1089/thy.1999.9.1227 Schirrmeister, 2001, Anatomical distribution and sclerotic activity of bone metastases from thyroid cancer assessed with F-18 Sodium Fluoride positron emission tomography, Thyroid, 11, 677, 10.1089/105072501750362754 Langsteger, 2004, 18 F DOPA PET vs 18 FDG PET in the follow up of MTC patients, Mol Imaging Biol, 6, 87 Langsteger, 2004, Comparison and first results of 18 F DOPA versus FDG PET in the follow up of MTC patients, Q J Nucl Med Mol Imaging, 48, 6 Moog, 1999, FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma, J Nucl Med, 40, 1407 Leonard, 1981, Multiple myeloma, Clin Radiol, 32, 291, 10.1016/S0009-9260(81)80043-8 Aoki, 2001, Nuclear imaging of bone tumors, Semin Musculoskelet Radiol, 5, 183, 10.1055/s-2001-15678 Brenner, 2003, PET imaging of osteosarcoma, J Nucl Med, 44, 930